Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 6/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | GRM7 | Q14831 | 2/20 | 0.39 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.37 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.34 |
| ▸ | MGLL | Q99685 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL649770 | 1.00 | HDAC8 (0.44) | HDAC8EPHX2GRM7CXCR1CXCR2 | |
| SCHEMBL3285577 | 1.00 | HDAC8 (0.44) | HDAC8EPHX2GRM7CXCR1CXCR2 | |
| SCHEMBL651197 | 1.00 | HDAC8 (0.44) | HDAC8EPHX2GRM7CXCR1CXCR2 | |
| SCHEMBL7246422 | 0.83 | HDAC8 (0.46) | HDAC8EPHX2MAPK1RIPK1 | |
| SCHEMBL2512120 | 0.83 | EPHX2 (0.56) | HDAC8EPHX2GRM7MAPK1 | |
| SCHEMBL2512118 | 0.83 | EPHX2 (0.56) | HDAC8EPHX2GRM7MAPK1 | |
| SCHEMBL2512863 | 0.83 | EPHX2 (0.56) | HDAC8EPHX2GRM7MAPK1 | |
| SCHEMBL13324488 | 0.81 | HDAC8 (0.44) | HDAC8EPHX2GRM7MAPK1 | |
| SCHEMBL12894154 | 0.81 | HDAC8 (0.44) | HDAC8EPHX2GRM7MAPK1 | |
| SCHEMBL3285401 | 0.81 | CXCR1 (0.49) | HDAC8EPHX2CXCR1CXCR2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119808-B2 | Tetrahydroquinoline derivatives as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-02-21 | — | — | US | disclosed |
| US-20110104315-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-05-05 | — | — | US | disclosed |
| US-7884113-B2 | Tetrahydroquinoline derivatives as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-02-08 | — | — | US | disclosed |
| US-7709647-B2 | Tetrahydroquinoline cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-05-04 | — | — | US | disclosed |
| US-20080200459-A1 | TETRAHYDROQUINOLINE CANNABINOID RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-08-21 | — | — | US | disclosed |
| WO-2006078697-A1 | BICYCLIC HETEROCYCLES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110104315-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | CNR2, CNR1, OPRL1 | HDAC8 2618/4885EPHX2 1569/4885GRM7 108/4885 |
| US-20080200459-A1 | TETRAHYDROQUINOLINE CANNABINOID RECEPTOR MODULATORS | CNR1, CNR2, GPR18 | HDAC8 2230/4885EPHX2 753/4885GRM7 144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.